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Background: Celecoxib is a selective cyclooxygenase (COX)-2 inhibitor that has been reported to reduce the risk of
breast cancer. In our previous study, celecoxib induced apoptosis and caused cell cycle arrest at the G0/G1 phase in
the breast cancer cell line MDA-MB-231, and its effects were mediated by downregulation of NF-κB signaling. The
NF-κB p65/RelA subunit may play a role in cell death through the activation of anti-apoptotic target genes
including the inhibitor of apoptosis (IAP) and Bcl-2 families, and inhibition of protein kinase B/Akt. The aim of the
present study was to investigate p65 as the potential target of celecoxib treatment and determine whether p65
overexpression can override the inhibitory effect of celecoxib on NF-κB activity and affect cell survival.
Methods: The effects of p65 overexpression on celecoxib-inhibited NF-κB transcriptional activity were examined by
western blotting, electrophoretic mobility shift assay (EMSA) and luciferase reporter gene assay. Cell viability and cell
death were evaluated by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide (MTT) assay, and the levels
of cleaved poly(ADP-ribose) polymerase (PARP) and caspase. Anti-apoptotic NF-κB target genes and cell cycle
regulators were examined by western blotting to screen for the expression of target genes under direct regulation
by p65.
Results: Overexpression of p65 increased NF-κB transcriptional activity and interfered with celecoxib-mediated
apoptosis as assessed by MTT assay and caspase-3, caspase-9, and PARP expressions. Exogenously overexpressed
p65 upregulated NF-κB-responsive genes, including anti-apoptotic genes such as survivin and XIAP, and the cell
cycle regulatory gene cyclin D1. However, p65 overexpression did not affect celecoxib-induced p-Akt inactivation,
suggesting that celecoxib might have separate molecular mechanisms for regulating Akt signaling independently
of its inhibition of NF-κB transcriptional activity.
Conclusions: p65 is a pivotal anti-apoptotic factor that can reverse celecoxib-induced growth inhibition in MDA-
MB-231 cells.
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Breast cancer is currently the most common form of
cancer affecting women and the sixth leading cause of
cancer-related death among women in China [1]. Des-
pite intensive cancer control efforts, its treatment* Correspondence: shanbaoen@yahoo.cn
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reproduction in any medium, provided the orremains a significant challenge for physicians [2]. Cele-
coxib is a selective cyclooxygenase (COX)-2 inhibitor
that has been widely marketed as an anti-inflammatory
drug with improved safety and lower toxicity than other
nonsteroidal anti-inflammatory drugs (NSAIDs). It
exerts potent anticancer effects in various tumor types,
including colon, skin, prostate, lung and breast cancers
[3-8]. The anti-tumorigenic effects of celecoxib are
mediated by cell growth inhibition, and induction of
apoptosis and cell cycle arrest. However, the exact mo-
lecular mechanisms involved are not yet well defined.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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celecoxib that are associated with several signaling path-
ways including FLICE-inhibitory protein (c-FLIP)/glyco-
gen synthase kinase-3 (GSK3) [9], Wnt/β-catenin [10],
IL-6/JAK2/STAT3 [11], nuclear factor-kappa B (NF-κB)
[12] and Akt [13].
The transcriptional factor NF-κB plays pivotal roles in
several cellular pathways and has received increasing at-
tention in recent years. The activation of NF-κB signal-
ing has been reported in breast cancer cell lines and
tumors [14,15]. The NF-κB family is composed of five
Rel-domain-containing proteins, p65/RelA, RelB, c-rel,
p50/NF-κB1 and p52/NF-κB2. In most cells, the pre-
dominant form of active NF-κB consists of a p65/p50
heterodimer that is retained in the cytoplasm in an in-
active form, and is bound by an inhibitory protein called
inhibitor of κB (IκB) [16,17]. The p65 subunit of NF-κB
is responsible for the transactivation of downstream
genes involved in the regulation of cell survival, cell
cycle distribution, and apoptosis [18]. In particular, p65
activation is a predictive factor of resistance to neoadju-
vant chemotherapy in breast cancer patients [19]. How-
ever, the specific role of p65 in breast cancer is still
unclear.
In a previous study, Basu et al. [13] reported that cele-
coxib inhibited the growth of MDA-MB-231 human
breast cancer cells through the inactivation of protein
kinase B/Akt. In addition, work from our group showed
that celecoxib could downregulate p65 level and the
transactivation activity of NF-κB, which promoted cell
apoptosis through the activation of the proapoptotic
proteins PARP and caspase-3 in MDA-MB-231 cells
[20]. However, we are not sure whether p65 is the direct
target of celecoxib. Moreover, the relationship between
Akt and NF-κB is controversial and elusive [21,22]. To
further our understanding of the effect of p65 in
MDA-MB-231 cells, p65 was overexpressed and its
role in counteracting celecoxib-induced apoptosis and
cell cycle arrest was evaluated. The results of our study
may provide insight into the mechanism of action of




Celecoxib with a purity of 98% was purchased from
Pharmacia (Skokie, IL) and dissolved in DMSO to gener-
ate a 100 mM stock solution that was stored at −20C.
Penicillin, streptomycin, Dulbecco’s modified eagle’s
medium (DMEM), fetal bovine serum (FBS), and Lipo-
fectamine 2000 were obtained from Invitrogen Life
Technologies (Invitrogen, USA). The NE-PER nuclear
and cytoplasmic extraction reagent kit and lightshift
chemiluminescent electrophoretic mobility shift assay(EMSA) kit were purchased from Pierce Biotechnology
(Pierce Biotechnology, Rockford, IL). The cell death de-
tection ELISAPLUS assay was purchased from Roche
(Roche Diagnostics Corp., Indianapolis, IN). All other
reagents were obtained from Sigma (St. Louis, MO). All
antibodies were from Santa Cruz Biotechnology (Santa
Cruz, CA).
Cell culture
MDA-MB-231 cells were obtained from the American
Type Culture Collection (ATCC) and routinely cultured
in DMEM containing 10% FBS in the presence of 100
U/ml penicillin and 100 μg/ml streptomycin. Cells were
incubated at 37C with 95% air and 5% carbon dioxide.
All cells were used in experiments during the linear
phase of growth.
Plasmids
The p65 expression vector (pcDNA3.1-p65) was a kind
gift from Dr Bu youquan, Chongqing Medical University.
The empty vector pcDNA3.1 was purchased from Invi-
trogen Life Technologies (Invitrogen, USA). The NF-κB
-responsive luciferase reporter construct (NF- κB-p65-Luc),
and its control plasmid (pRL-TK) were purchased from
Promega (Promega,USA).
Transient transfection and luciferase assay
MDA-MB-231 cells were seeded at a concentration of
5 × 105 cells/well in 24-well plates. After overnight cul-
ture and reaching 80% confluence, the cells in each well
were transiently transfected with 1 μg DNA consisting
of NF-κB-p65-Luc and pRL-TK in serum-free medium
according to the manufacturer’s protocol. After 12 h, the
transfection mix was removed and replaced with complete
medium. Twenty-four hours after co-transfection, cells
were harvested and luciferase activity was determined
using Luciferase Assay System (Promega, E1500).
Cell viability assay
MDA-MB-231 cells were seeded at a density of 5 × 103
cells per well in 200 μl of DMEM medium into 96-well
plates, and cultured overnight. Cells were treated with
80 μM celecoxib and incubated for 24, 48, and 72 h. At
different time points, the medium was replaced with
100 μl fresh medium containing 0.5 mg/ml 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl tetrasodium bromide
(MTT). Four hours after the addition of MTT, the super-
natants were removed and discarded, and 150 μl of
DMSO was added to each well to dissolve the crystals.
Cell viability was determined with a microplate reader at a
wavelength of 490 nm. All plates had control wells con-
taining medium without cells to obtain a value for back-
ground luminescence, which was subtracted from the test
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cate and repeated at least three times.
Flow cytometry for cell cycle analysis
Flow cytometric analyses were performed to determine
the cell cycle distribution. MDA-MB-231 cells were trea-
ted with vehicle or 80 μM celecoxib for 24 h, and then
harvested by trypsinization and fixed with 70% ethanol.
Cells were stained for total DNA content with a solution
containing 50 μg/ml propidium iodide (PI) and 100
μg/ml RNase I in PBS for 30 min at 37C. Cell cycle
distribution was then analyzed with the FACS Calibur
Flow Cytometer (BD, USA). The proportions of cells in
the G0/G1, S and G2/M phases were analyzed by FACS
and a DNA software program. This experiment was
repeated three times and the results were averaged.
EMSA
The DNA binding activity of NF-κB was confirmed with
a biotin-labeled oligonucleotide NF-κB probe (5’-AGTT
GAGGGGACTTTCCCAGGC-3’). Cells were plated in
6-well plates and grown to 70% confluency. Cells were
preincubated with celecoxib for 24 h, after which nuclear
extracts (10 μg) were prepared according to the manu-
facturer’s protocol (Pierce, 20148). After incubation with
1 μg/μl of poly (deoxyinosinic-deoxycytidylic acid) in
binding buffer for 30 min at 4C, the nuclear extract
mixed with probe was resolved on a 6% polyacrylamide
gel at 100 V for 1 h, transferred to a nylon membrane,
and subjected to UV crosslinking, and membranes were
exposed to X-ray film to visualize the bands.
Apoptosis ELISA
Cells were plated in 96-well plates, starved by serum
deprivation and allowed to attach for 24 h. Cells were
pretreated with celecoxib at a concentration of 80 μM
for 24, 48, and 72 h. After treatment, non-adherent and
adherent cells were collected and apoptosis was assessed
using the Cell Death Detection ELISAPLUS Assay accord-
ing to the manufacturer's instructions. Measurements
were made using an ELISA reader at 405 nm and the
results were expressed as the ratio of the absorbance of
the celecoxib-treated cells to the absorbance of un-
treated cells. Treatment with each concentration of cele-
coxib was repeated in 6 wells, and each treated sample
was normalized to media controls.
Western blot analysis
For analysis of protein expression, cells were washed
twice with ice-cold phosphate buffered saline (PBS) and
extracted using the NE-PER nuclear and cytoplasmic ex-
traction kit according to the manufacturer’s instructions.
Proteins (20 μg/lane) were separated by 10% SDS-PAGE
and electrotransferred to nitrocellulose. Membraneswere blocked for 1 h at room temperature in 5% milk.
NF-κB p65, caspase-3, caspase-9, PARP, cyclinD1, cyclin
E, CDK2, CDK4, CDK6, p21, p27, Bax, Bcl-2, Bcl-xl,
XIAP, survivin and GAPDH were detected by incubating
the transferred membrane overnight at 4C with the
indicated mouse polyclonal antibody (Santa Cruz, USA)
at a 1:1000 dilution, then washing and incubating with
the appropriate HRP-conjugated secondary antibodies
(1:5000) for 1 h at room temperature. Protein bands
were visualized using the enhanced chemiluminescence
method. Relative protein levels were calculated by
normalization to the amount of GAPDH protein. Data
shown are representative of 3 independent experiments.
Statistical analysis
Results were expressed as mean values ± SD. Differences
between groups were compared by one-way ANOVA,
and the Student’s t test was used to evaluate statistical
significance using SPSS software. A value of less than
0.05 (P < 0.05) was considered statistically significant.
Results
Overexpression of p65 increases NF-κB transcriptional
activity in MDA-MB-231 cells
MDA-MB-231 cells express constitutively active NF-κB,
and its activity could be significantly suppressed by cele-
coxib in our preliminary study. To further examine the
biological functions of p65, a recombinant plasmid
expressing p65 (p65cDNA) was constructed and trans-
fected into MDA-MB-231 cells. Western blotting results
confirmed that p65 expression was strongly upregulated
in p65-transfected cells even after celecoxib (80 μM)
treatment. However, there were no significant differences
in p50 and IκBα expression between control- and p65-
transfected cells.
Overexpression of p65 caused a significant increase in
NF-κB transcriptional activity as measured after 12 and
24 h by EMSA and luciferase reporter assays, respect-
ively (Figure 1B and C). NF-κB transcriptional activity
was only slightly affected by celecoxib pretreatment after
12 h in control- and p65-transfected cells, whereas sig-
nificant inhibition was observed after 24 h. As expected,
NF-κB transcriptional activity was significantly higher in
p65-transfected cells even after celecoxib treatment.
Overexpression of p65 does not affect Akt signaling
A study by Basu [13] and our previous study indicated
that celecoxib induced apoptosis and cell cycle arrest of
breast cancer cells by blocking Akt and NF-κB activation
in vitro. The crosstalk between the Akt and NF-κB sig-
naling pathways is not well understood. To determine
the effects of p65 overexpression on Akt activation in
MDA-MB-231 cells, cells were transiently transfected
with p65cDNA and empty vector. As shown in Figure 2,
Figure 1 Overexpression of p65 increases NF-κB transcriptional activity. (A) Cells were transfected with p65cDNA or empty vector and
treated with celecoxib (80 μM) for 12 h. (B) NF-κB DNA binding activity was evaluated by EMSA in cells transfected with p65cDNA or empty
vector. (C) NF-κB DNA binding activity was evaluated by luciferase reporter gene assay in cells transfected with p65cDNA or empty vector. *P <
0.05, significantly different from empty vector transfected cells. #P < 0.05, significantly different from empty vector transfected cells after
celecoxib treatment.
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S473 and T308. However, overexpression of p65 did not
have a significant effect on the phosphorylation of Akt.
p65 overexpression decreases celecoxib-induced
apoptosis
To assess the effects of p65 overexpression on
celecoxib-induced apoptosis, MDA-MB-231 cells were
transfected with p65cDNA or empty vector and treated
with 80 μM celecoxib for different time. The results of
the MTT assay showed that treatment with 80 μM cele-
coxib for 24 h caused a loss of cell viability of 65.3%,
which was reversed by p65cDNA transfection. TheseFigure 2 Inactivation of p-Akt by celecoxib is unaffected by overexprresults indicated that p65 overexpression abrogated
celecoxib-induced cell death.
The cell death detection ELISAPLUS assay was used to
assess the effect of p65 overexpression on celecoxib-
induced cell death. The results indicated a 1.5-fold de-
crease in DNA fragmentation in p65-overexpressing
cells compared with cells transfected with empty vector
after treatment with celecoxib for 48 h. Caspases are re-
sponsible for many of the biochemical and morpho-
logical changes that occur during apoptosis [23]. In a
previous study, we reported that activation of caspase-9,
caspase-3 and PARP contributed to celecoxib-induced
apoptosis in MDA-MB-231 cells. In the present study,ession of p65.
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caspase-9, caspase-3 and PARP than mock-transfected
controls after celecoxib treatment (Figure 3C).
p65 overexpression affects celecoxib downregulation of
NF-κB-responsive anti-apoptotic genes
The expressions of bcl-2, bcl-xL and bax were not sig-
nificantly affected in control- and p65-overexpressingFigure 3 p65 overexpression suppresses celecoxib-induced cell death
treated with celecoxib (80 μM) for 12 and 24 h. Cell death was assessed by
ELISAPLUS Assay. (C) Apoptosis was assessed by western blotting against clecells (Figure 4), but were reduced to similar degrees by
celecoxib treatment in control and p65-overexpressing
cells (Figure 4). These results indicated that the effect of
celecoxib on the induction of apoptosis in MDA-MB
-231 cells was mediated by bcl-2 family members, but
not directly regulated by p65 expression, suggesting that
p65 was not the only pivotal molecule regulating MDA-
MB-231 cell survival.. (A) Cells were transfected with p65cDNA or empty vector and
MTT assay. (B) Cell apoptosis was assessed by Cell Death Detection
aved PARP in whole-cell lysates.
Figure 4 Effect of p65 overexpression on anti-apoptotic NF-κB target genes including Bcl-2 family and IAP family proteins.
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of potent endogenous inhibitors that regulate apoptosis
through direct inhibition of caspases or pro-caspases
and are transcriptionally regulated by NF-κB [24]. Prior
studies have shown that XIAP and suvivin are closely
tied to the expression of the NF-κB p65 subunit [25,26].
As shown in Figure 4, XIAP and surivin expressions
were significantly upregulated in p65-overexpressing
cells compared to control cells. Celecoxib treatment
reduced XIAP and surivin expression in mock-
transfected cells but had no effect in p65-overexpressing
cells at any time point.Table 1 p65 overexpression affects celecoxib-induced cell
cycle arrest
Group G0/G1 G2/M S
pcDNA3.1 51.78 ± 5.09 19.81 ± 2.09 28.41 ± 2.07
p65cDNA 43.29 ± 4.12* 22.37 ± 1.76 34.34 ± 3.15*
pcDNA3.1 + 80μM celecoxib 62.07 ± 6.13 16.05 ± 1.98 21.88 ± 2.59
p65cDNA + 80μM celecoxib 50.98 ± 6.17# 20.31 ± 2.36# 28.71 ± 3.03#
*P < 0.05, pcDNA3.1vs p65cDNA;
#P < 0.05, pcDNA3.1 + 80 μM celecoxib vs p65cDNA + 80 μM celecoxib.Celecoxib-induced G0/G1 phase cell cycle arrest is
attenuated by p65 overexpression
Because changes in apoptosis alone could not com-
pletely account for the observed growth-inhibitory
effects of celecoxib in MDA-MB-231 cells, cell cycle
phase distribution was analyzed by flow cytometry. Fol-
lowing synchronization, p65cDNA-transfected cells and
control cells were serum starved for 24 h and then trea-
ted with celecoxib for 24 h. Celecoxib treatment signifi-
cantly increased the percentage of G0/G1 phase cells,
and decreased the number of S and G2/M phase cells
(Table 1). However, the celecoxib-induced increase in
the number of G0/G1 phase cells was significantly
reduced by p65 overexpression. Interestingly, basal cell
cycle distribution in control cells was unaffected by p65
overexpression. These results indicated that p65 overex-
pression attenuated celecoxib-induced G1 phase arrest,but did not affect the cell cycle in wild MDA-MB-231
cells.The effect of celecoxib on cell cycle regulatory proteins is
modulated by p65 overexpression
To identify the potential contributors to the observed
G0/G1 cycle arrest, cyclins, CDKs and CDKIs, which are
associated with the G1/S checkpoint were analyzed by
western blotting. As shown in Figure 5, cyclin D1, cyclin
E, CDK2 and CDK4 were downregulated in a similar
manner by celecoxib treatment. Compared with cells
transfected with empty vector, p65-overexpressing cells
showed high levels of cyclin D1 after celecoxib treat-
ment. In contrast, no appreciable differences in the
levels of cyclin E, CDK2 and CDK4 were observed be-
tween cells transfected with p65cDNA and empty vector.
Among the CDKIs investigated, the expressions of p21
and p27 were upregulated in response to celecoxib treat-
ment. p65 overexpression abrogated the celecoxib-
induced p21 increment, but had no effect on p27.
Figure 5 Examination of cell cycle regulators influenced by overexpression of p65.
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We have shown previously that celecoxib could inhibit
COX-2 and p65 expression levels, which promotes apop-
tosis in human MDA-MB-231 breast cancer cells [20].
Until now, the pro-apopotic effects of celecoxib have
been proved to be associated with multiple intracellular
signaling pathways including NF-κB, Akt and caspases,
which interact to regulate programmed cell death [27].
To better understand the NF-κB/Akt signaling interac-
tions implicated in celecoxib-mediated apoptosis, the
present study overexpressed p65, the major transactivat-
ing subunit of NF-κB, in MDA-MB-231 cells and evalu-
ated effects on celecoxib-induced Akt activation, NF-κB
transcriptional activity, apoptosis and cell cycle distribu-
tion. In this study, overexpression of p65 in MDA-MB
-231 cells enhanced p65 protein expression and the basal
NF-κB DNA binding activity. However, transfection of
MDA-MB-231 cells with p65cDNA had no significant
effect on the NF-κB p50 subunit and the inhibitory mol-
ecule IκB. Celecoxib treatment, at 80 μM, which opti-
mally induces apoptosis in MDA-MB-231 cells [20],
inhibited NF-κB transcriptional activity and expression
of NF-κB target genes. Celecoxib suppression of NF-κB
was blocked in p65 transfectants since activity remained
at least 2-fold higher than in mock-transfected cells.
These results suggest that the exogenous upregulation of
p65 could attenuate the inactivation of NF-κB caused by
celecoxib treatment.Akt has been shown to regulate cell survival and sup-
press apoptosis by stimulating the transactivation poten-
tial of the NF-κB p65 subunit [28]. In contrast, the NF-κB
signaling pathway has also been reported to function up-
stream of Akt. Overexpression of p65 led to Akt phos-
phorylation in the absence of extracellular stimulatory
factors and caused an increase in the expression of Akt at
the mRNA and protein levels [21]. In MDA-MB-231 cells,
celecoxib could inactivate pAkt with increased activation
of proapoptotic protein [13]. In our previous study, we
also found that celecoxib could inhibit cell growth, induce
apoptosis and alter cell cycle distribution by blocking NF-κB
signaling [20]. However, the present results indicated that
overexpression of p65 had no effect on the phosphorylation
of Akt, suggesting that Akt might play a role in upstream
signaling pathways or via NF-κB-independent pathway in
MDA-MB-231 cells. The precise molecular mechanisms
remain to be determined.
NF-κB p65 can be an activator and repressor of its tar-
get genes depending upon the manner in which it is
induced [29]. For example, Anto et al. [30] reported that
overexpression of p65 in L929 mouse fibrosarcoma cells
caused resistance to curcumin-induced apoptosis. Op-
posite results were reported by Collett et al. [31], who
showed that overexpression of p65 potentiated curcumin-
induced apoptosis in HCT116 human colon cancer cells.
Besides, the role of p65 in the carcinogenic process is also
complex and may involve the interaction of multiple
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[32] reported that increased expression of p65 was corre-
lated with colorectal tumorigenesis and promoted tumor
progression. Conversely, Ricca et al. [33] reported that
overexpression of p65 in MCF7/ADR cells reduced their
tumorigenic ability in nude mice. The present study
showed that overexpression of p65 could antagonize
celecoxib-mediated apoptosis, as assessed by MTT assay
and cell death fragment detection. Furthermore, trans-
fected p65cDNA resulted in inhibition of caspase-3, -9
and PARP cleavage in MDA-MB-231 cells, which may be
attributed to suppression of NF-κB-dependent transcrip-
tional activity and expression of NF-κB-dependent anti-
apoptotic genes. Therefore, we investigated two NF-κB
-dependent target gene families, namely IAP family mem-
bers and Bcl-2 family proteins. Results showed that p65
upregulation counteracted the celecoxib-induced inhib-
ition of survivin and XIAP, while exerted no effects on
Bcl-2 family members. The IAP family was confirmed to
be regulated by NF-κB signaling and closely tied to breast
cancer development [34]. The current study indicates that
survivin and XIAP could be directly regulated by NF-κB
p65 subunit, thus functioning anti-apoptosis in breast can-
cer cells. Although Bcl-2 has NF-κB binding sites and can
be regulated by p65 [35], the expression of Bcl-2 family
members remained unaffected in both mock transfectants
and p65-overexpressing cells before and after celecoxib
treatment. It is speculated that a putative increase in Bcl-2
mRNA might be counteracted by micro-RNA-mediated
translational arrest [36].
Cell proliferation is the result of a rapid shift from a
quiescent state to the progression of the cell cycle [37].
Flow cytometric results showed that celecoxib induced
MDA-MB-231 cell cycle arrest at the G0/G1 phase, and
this effect was suppressed by p65cDNA transfection.
Progress in the eukaryotic cell cycle is driven by protein
kinase complexes consisting of cyclins and CDKs. CDK
activity is regulated negatively by a group of proteins
called CDK inhibitors, including the protein p21 and
p27 [38]. In the present study, cyclin D1 was increased
in p65-overexpressing cells even in the presence of cele-
coxib, and p65 overexpression caused the inhibition of
p21, suggesting a possible protective role for p65 expres-
sion in celecoxib-mediated cell cycle arrest. Collectively,
these results indicated that p65 may have a direct role in
regulating cell cycle progression, facilitating the transi-
tion of cells from G1 to S phase.
In conclusion, the present results strongly suggest that
p65 expression has a protective role against celecoxib-
mediated cell death of human breast cancer. In light of
such a scenario, targeting p65 subunit or transfection
with anti-p65 intrabody may enhance the anti-tumor ef-
fect of celecoxib in breast cancer treatment. Given that
all current clinical anti-cancer drugs have reportedincidences of drug resistance, development of experi-
mental therapeutic aimed at new proliferative targets are
of increasing importance. Further investigation into the
molecular mechanism of p65 action may offer a novel
approach to interfere with NF-κB activity in the nuclear
compartment for treating breast cancer as well as other
tumors.
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